News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiomed (ABMD) Release: PROTECT II Demonstrates That Patients Undergoing Extensive Revascularization Benefit the Most from Impella Support


11/9/2011 11:02:09 AM

DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the final analysis from the PROTECT II trial at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) meeting.

PROTECT II is the first study to examine this cohort of complex patients with high clinical risk, low ejection fraction, and high STS and SYNTAX scores.

Read at BioSpace.com


comments powered by Disqus
Abiomed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES